REUTERS
February 7, 2022 at 15:55 JST
A factory in Gifu Prefecture that manufactures a new vaccine for COVID-19 for drug maker Shionogi & Co. (Provided by Shionogi & Co.)
Japanese Prime Minister Fumio Kishida said on Monday the government would consider granting conditional early approval for the oral COVID-19 treatment being developed by Shionogi & Co Ltd.
Kishida told a televised parliamentary committee meeting that provided the drug's safety and efficacy are confirmed by clinical trials “we would like to review it promptly.”
It was reported earlier that Japan is considering allowing Shionogi to start selling the antiviral oral tablets as early as this spring after giving the pharmaceutical company special permission to skip the final stage of the clinical trial.
Shionogi said on Jan. 17 it started a Phase III trial in Japan of its COVID-19 vaccine candidate S-268019 that will compare its results to that of an approved vaccine.
New clinical trial method speeds up Shionogi vaccine rollout
September 13, 2021
Shionogi to start final clinical trial for new COVID-19 vaccine
November 2, 2021
Japan’s Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine
October 21, 2021
New tech will let cities detect virus in sewage with higher sensitivity
May 31, 2021
Drug firms enter final leg of race for COVID-19 oral antivirals
September 30, 2021
Under new plan, clinical trials for COVID vaccines simplified
October 26, 2021
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
